Physician profile
Kenneth Kovach
NPI 1881691186
$1,350.09
in general payments reported to CMS, 2019-2025
21 companies · $516 in 2025
The $516 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.06 · 2020: $20.91 · 2022: $102 · 2023: $206 · 2024: $476 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.53 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.72 | 2022-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $187.23 | 2024-2025 | |
| Vifor Pharma, INC. | $137.85 | 2020-2025 | Veltassa |
| Glaxosmithkline, LLC. | $127.72 | 2023-2025 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $118.43 | 2023-2024 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $74.73 | 2022-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $72.60 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.88 | 2022-2024 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.62 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $50.57 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $36.00 | 2024 | Rayaldee |
| Recor Medical INC | $29.16 | 2024 | Paradise Renal Denervation System |
| Abbott Laboratories | $28.41 | 2022-2023 | Freestyle Libre 2 |
| Calliditas Therapeutics US INC. | $24.34 | 2025 | Tarpeyo |
| Ardelyx, INC. | $22.28 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $20.19 | 2023 | Lupkynis |
| Nxstage Medical, INC. | $16.91 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.39 | 2025 | |
| Cormedix INC. | $14.42 | 2024 | Defencath |
| Fresenius USA Marketing, INC. | $14.27 | 2025 | Velphoro |
| Genentech USA, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kovach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.